比高集團(08220.HK):王競強辭任獨立非執行董事
格隆匯5月19日丨比高集團(08220.HK)公吿,獨立非執行董事王競強於香港證券及期貨事務監察委員會根據香港法例第571章證券及期貨條例第214(1)(b)、(c)及(d)條向香港高等法院原訴法庭提交日期為2022年5月12日呈請中被列為應訴人之一。
王競強因有意投入更多時間至其個人事務及其他業務承擔,已辭任獨立非執行董事,自2022年5月20日起生效。
隨王競強辭任後,(i)王競強亦不再擔任公司審核委員會主席,以及公司薪酬委員會及公司提名委員會各自成員,及(ii)徐永得(獨立非執行董事及審核委員會成員)已獲委任為審核委員會主席。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.